Trial Profile

Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI) Treated With Multitarget Antiviral Therapy (MT-ART)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobicistat/darunavir (Primary) ; Emtricitabine/tenofovir alafenamide (Primary) ; Dolutegravir
Indications HIV infections; HIV-1 infections
Focus Therapeutic Use
Acronyms INACTION; P25-INACTION

Most Recent Events

30 Oct 2021 Primary endpoint has not been met (the change of total HIV-DNA level from baseline to 48 weeks.) as per Results presented at the 18th European AIDS Conference
30 Oct 2021 Results presented at the 18th European AIDS Conference
29 Aug 2021 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com